TrialPsychopharmacology2018

Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.

Jennifer R Schroeder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.